We analyzed clinical characteristics of patients with AML from Cohort 1, including age, gender, ELN 2017, the mutations of NPM1 and FLT3, and CEBPA Biallelic status (Table 1). This evidence concerns the gene CEBPA and acute myeloid leukemia.